Identification of potential therapeutic antimicrobial peptides against Acinetobacter baumannii in a mouse model of pneumonia

• Published in: Scientific reports Vol. 11; no. 1; p. 7318
• Main Authors: Jung, Chiau-Jing, Liao, You-Di, Hsu, Chih-Chieh, Huang, Ting-Yu, Chuang, Yu-Chung, Chen, Jeng-Wei, Kuo, Yu-Min, Chia, Jean-San
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326/22; 631/326/41; Acinetobacter baumannii; Animal models; Antibiotic resistance; Antimicrobial activity; Antimicrobial agents; Antimicrobial peptides; Biofilms; Hospitals; Humanities and Social Sciences; Intravenous administration; multidisciplinary; Nosocomial infection; Peptides; Pneumonia; Science; Science (multidisciplinary); Toxicity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-86844-5

Acinetobacter baumannii -induced nosocomial pneumonia has become a serious clinical problem because of high antibiotic resistance rates. Antimicrobial peptides (AMP) are an ideal alternative strategy due to their broad-spectrum of antimicrobial activity and low incidence of bacterial resistance. However, their application is limited by toxicity and stability in vivo. The present study used a mouse model to directly identify potential AMPs effective for treatment of A. baumannii -induced pneumonia. Fifty-eight AMPs were screened and two identified (SMAP-29 and TP4) to have prophylactic effects which prevented the death of mice with pneumonia. Furthermore, two TP4 derivatives (dN4 and dC4) were found to have therapeutic activity in pneumonia mouse models by peritoneal or intravenous administration. Both dN4 and dC4 also inhibited and/or eliminated A. baumannii biofilms at higher doses. Taken together, these data suggest the AMP derivatives dN4 and dC4 represent a potential treatment strategy for A. baumannii- induced pneumonia.